Luteolin as a potential hepatoprotective drug: Molecular mechanisms and treatment strategies

被引:44
作者
Yao, Chenhao [1 ]
Dai, Shu [1 ]
Wang, Cheng [1 ]
Fu, Ke [1 ]
Wu, Rui [1 ]
Zhao, Xingtao [1 ]
Yao, Yuxin [1 ]
Li, Yunxia [1 ]
机构
[1] Chengdu Univ Tradit Chinese Med, State Key Lab Southwestern Chinese Med Resources, Key Lab Standardizat Chinese Herbal Med, Sch Pharm,Minist Educ, Chengdu 611137, Peoples R China
基金
中国国家自然科学基金;
关键词
Luteolin; Metabolic associated fatty liver disease; Hepatic fibrosis; Liver cancer; ACTIVATED PROTEIN-KINASE; FATTY LIVER-DISEASE; INSULIN-RESISTANCE; OXIDATIVE STRESS; INTESTINAL-ABSORPTION; HEPATIC STEATOSIS; SIGNAL TRANSDUCER; GENE-EXPRESSION; INNATE IMMUNITY; HEPG2; CELLS;
D O I
10.1016/j.biopha.2023.115464
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Luteolin is a flavonoid widely present in various traditional Chinese medicines. In recent years, luteolin has received more attention due to its impressive liver protective effect, such as metabolic associated fatty liver disease, hepatic fibrosis and hepatoma. This article summarizes the pharmacological effects, pharmacokinetic characteristics, and toxicity of luteolin against liver diseases, and provides prospect. The results indicate that luteolin improves liver lesions through various mechanisms, including inhibiting inflammatory factors, reducing oxidative stress, regulating lipid balance, slowing down excessive aggregation of extracellular matrix, inducing apoptosis and autophagy of liver cancer cells. Pharmacokinetics research manifested that due to metabolic effects, the bioavailability of luteolin is relatively low. It is worth noting that appropriate modification, new delivery systems, and derivatives can enhance its bioavailability. Although many studies have shown that the toxicity of luteolin is minimal, strict toxicity experiments are still needed to evaluate its safety and promote its reasonable development. In addition, this study also discussed the clinical applications related to luteolin, indicating that it is a key component of commonly used liver protective drugs in clinical practice. In view of its excellent pharmacological effects, luteolin is expected to become a potential drug for the treatment of various liver diseases.
引用
收藏
页数:16
相关论文
共 188 条
[1]   Protection against nonalcoholic steatohepatitis through targeting IL-18 and IL-1alpha by luteolin [J].
Abu-Elsaad, Nashwa ;
El-Karef, Amr .
PHARMACOLOGICAL REPORTS, 2019, 71 (04) :688-694
[2]   Luteolin loaded on zinc oxide nanoparticles ameliorates non-alcoholic fatty liver disease associated with insulin resistance in diabetic rats via regulation of PI3K/AKT/FoxO1 pathway [J].
Ahmed, Esraa S. A. ;
Mohamed, Hebatallah E. ;
Farrag, Mostafa A. .
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2022, 36
[3]   Antagonistic Efficacy of Luteolin against Lead Acetate Exposure-Associated with Hepatotoxicity is Mediated via Antioxidant, Anti-Inflammatory, and Anti-Apoptotic Activities [J].
Al-Megrin, Wafa A. ;
Alkhuriji, Afrah F. ;
Yousef, Al Omar S. ;
Metwally, Dina M. ;
Habotta, Ola A. ;
Kassab, Rami B. ;
Moneim, Ahmed E. Abdel ;
El-Khadragy, Manal F. .
ANTIOXIDANTS, 2020, 9 (01)
[4]   The flavonoids diosmetin and luteolin exert synergistic cytostatic effects in human hepatoma HepG2 cells via CYP1A-catalyzed metabolism, activation of JNK and ERK and P53/P21 up-regulation [J].
Androutsopoulos, Vasilis P. ;
Spandidos, Demetrios A. .
JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2013, 24 (02) :496-504
[5]   Role of innate immunity in the development of hepatocellular carcinoma [J].
Aravalli, Rajagopal N. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (43) :7500-7514
[6]   Innate Immunity and Inflammation in NAFLD/NASH [J].
Arrese, Marco ;
Cabrera, Daniel ;
Kalergis, Alexis M. ;
Feldstein, Ariel E. .
DIGESTIVE DISEASES AND SCIENCES, 2016, 61 (05) :1294-1303
[7]   Burden of liver diseases in the world [J].
Asrani, Sumeet K. ;
Devarbhavi, Harshad ;
Eaton, John ;
Kamath, Patrick S. .
JOURNAL OF HEPATOLOGY, 2019, 70 (01) :151-171
[8]   The detrimental effects of lead on human and animal health [J].
Assi, Mohammed Abdulrazzaq ;
Hezmee, Mohd Noor Mohd ;
Haron, Abd Wahid ;
Sabri, Mohd Yusof Mohd ;
Rajion, Mohd Ali .
VETERINARY WORLD, 2016, 9 (06) :660-671
[9]   Liver fibrosis [J].
Aydin, M. Merve ;
Akcali, Kamil Can .
TURKISH JOURNAL OF GASTROENTEROLOGY, 2018, 29 (01) :14-21
[10]   Molecular pathways of nonalcoholic fatty liver disease development and progression [J].
Bessone, Fernando ;
Valeria Razori, Maria ;
Roma, Marcelo G. .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2019, 76 (01) :99-128